Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma after Previous Platinum-Based Chemotherapy for Metastatic Disease.
Fiche publication
Date publication
août 2021
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LADOIRE Sylvain
Tous les auteurs :
Wong RL, Ferris LA, Do OA, Holt SK, Ramos JD, Crabb SJ, Sternberg CN, Bellmunt J, Ladoire S, De Giorgi U, Harshman LC, Vaishampayan UN, Necchi A, Srinivas S, Pal SK, Niegisch G, Dorff TB, Galsky MD, Yu EY
Lien Pubmed
Résumé
Fit patients with metastatic urothelial carcinoma (mUC) receive first-line platinum-based combination chemotherapy (fPBC) as standard of care and may receive additional later-line chemotherapy after progression. Our study compares outcomes with subsequent platinum-based chemotherapy (sPBC) versus subsequent non-platinum-based chemotherapy (sNPBC).
Mots clés
Antineoplastic agents, Cisplatin, carboplatin, Drug therapy, combination, Platinum compounds, Urinary bladder neoplasms, Urologic neoplasms
Référence
Oncologist. 2021 Aug 6;: